Urotensin-II receptor antagonists: Synthesis and SAR of N-cyclic azaalkyl benzamides

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 3950-3954

  Jin, Jian ^a   An, Ming ^a   Sapienza, Anthony ^a   Aiyar, Nambi ^a   Naselsky, Diane ^a   Sarau, Henry M ^a   Foley, James J ^a   Salyers, Kevin L ^a   Knight, Steven D ^a   Keenan, Richard M ^a   Rivero, Ralph A ^a   Dhanak, Dashyant ^a   Douglas, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

N cyclic azaalkyl benzamides; Urotensin II receptor antagonist; UT antagonist

Indexed keywords

BENZAMIDE DERIVATIVE; CYTOCHROME P450; HETEROCYCLIC COMPOUND; PIPERIDIN 4 YLOXY DERIVATIVE; UROTENSIN II; UROTENSIN II RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FLUOROMETRY; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

BENZAMIDES; BINDING SITES; CHEMISTRY, PHARMACEUTICAL; DIAMINES; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47149105824     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.019     Document Type: Article

References (34)

1. Bern H.A., and Lederis K. J. Endocrinol. 45 (1969) xi
2. Bern H.A., Pearson D., Larson B.A., and Nishioka R.S. Recent Prog. Horm. Res. 41 (1985) 533
3. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W., Ohlstein E.H., Bergsma D.J., and Douglas S.A. Nature 401 (1999) 282
4. Douglas S.A., Dhanak D., and Johns D.G. Trends Pharmacol. Sci. 25 (2004) 76
5. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., and Hirata Y. J. Hypertens. 19 (2001) 2185
6. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. J. Hypertens. 22 (2004) 1341
7. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Lancet 359 (2002) 1990
8. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Circulation 106 (2002) 2877
9. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Lancet 360 (2002) 545
10. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., Schramm M., Guelker H., and Stasch J.P. Int. J. Cardiol. 94 (2004) 93
11. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., and Molenaar P. Am. J. Physiol. 285 (2003) H1576
12. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. J. Med. Chem. 45 (2002) 1799
13. Croston G.E., Olsson R., Currier E.A., Burstein E.S., Weiner D., Nash N., Severance D., Allenmark S.G., Thunberg L., Ma J., Mohell N., O'Dowd B., Brann M.R., and Hacksell U. J. Med. Chem. 45 (2002) 4950
14. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S., Fischli W., Hess P., Mathys B., Morrison K., Muller C., Muller C., Nayler O., Qiu C., Rey M., Scherz M.W., Velker J., Weller T., Xi J., and Ziltener P. J. Pharmacol. Exp. Ther. 311 (2004) 204
15. Jin J., Dhanak D., Knight S.D., Widdowson K., Aiyar N., Naselsky D., Sarau H.M., Foley J.J., Schmidt D.B., Bennett C.D., Wang B., Warren G.L., Moore M.L., Keenan R.M., Rivero R.A., and Douglas S.A. Bioorg. Med. Chem. Lett. 15 (2005) 3229
16. Douglas S.A., Behm D.J., Aiyar N.V., Naselsky D., Disa J., Brooks D.P., Ohlstein E.H., Gleason J.G., Sarau H.M., Foley J.J., Buckley P.T., Schmidt D.B., Wixted W.E., Widdowson K., Riley G., Jin J., Gallagher T.F., Schmidt S.J., Ridgers L., Christmann L.T., Keenan R.M., Knight S.D., and Dhanak D. Br. J. Pharmacol. 145 (2005) 620
17. Lehmann F., Pettersen A., Currier E.A., Sherbukhin V., Olsson R., Hacksell U., and Luthman K. J. Med. Chem. 49 (2006) 2232
18. Luci D.K., Ghosh S., Smith C.E., Qi J., Wang Y., Haertlein B., Parry T.J., Li J., Almond H.R., Minor L.K., Damiano B.P., Kinney W.A., Maryanoff B.E., and Lawson E.C. Bioorg. Med. Chem. Lett. 17 (2007) 6489
19. Jin J., Wang Y., Wang F., Shi D., Erhard K.F., Wu Z., Guida B.F., Lawrence S.K., Behm D.J., Disa J., Vaidya K.S., Evans C., McMillan L.J., Rivero R.A., Neeb M.J., and Douglas S.A. Bioorg. Med. Chem. Lett. 18 (2008) 2860
20. For recent reviews, see:. Jin J., and Douglas S.A. Expert Opin. Ther. Patents 16 (2006) 467
21. Dhanak D., Neeb M.J., and Douglas S.A. Ann. Rep. Med. Chem. 38 (2003) 99
22. i-mobilization assay details, see Ref. 2.
23. The radioligand binding assay was used as the primary assay to generate SAR.
24. The biological assay results in the paper are a mean of at least two determinations unless otherwise noted.
25. 1H NMR and/or LCMS, and had purity greater than 90%.
26. For experimental details, see: Dhanak, D.; Knight, S. D.; Jin, J.; Keenan, R. M. WO Patent 2001045711-A1, 2001; Chem. Abstr. 2001, 135, 76785.
27. For experimental details, see: Dhanak, D.; Knight, S. D.; Jin, J.; Rivero, R. A. WO Patent 2002078641-A2, 2002; Chem. Abstr. 2002, 137, 294884.
28. Dhanak, D.; Knight, S. D.; Jin, J.; Rivero, R. A.; Sapienza, A. WO Patent 2002079188-A1, 2002; Chem. Abstr. 2002, 137, 294980.
29. Jin J., Graybill T.L., Wang M.A., Davis L.D., and Moore M.L. J. Comb. Chem. 3 (2001) 97
30. Available from Polymer Laboratories, part number: 1466-6689, 150-300 μM, 1.5 mmol/g loading.
31. Compound 15c is a racemic mixture of two enantiomers.
32. Compounds 16b, 16c and 16d were prepared similarly as 1a, 11a and 15a. For experimental details, see: Dhanak, D.; Knight, S. D.; Warren, G. L.; Jin, J.; Widdowson, K. L.; Keenan, R. M. WO Patent 2001045700-A1, 2001; Chem. Abstr. 2001, 135, 71313.
33. Dhanak, D.; Knight, S. D.; Jin, J.; Rivero, R. A. WO Patent 2002079155-A1, 2002; Chem. Abstr. 2002, 137, 294885.
34. For rat UT receptor radioligand binding assay details, see:. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., Ao Z., Maleeff B.E., Naselsky D., Disa J., and Aiyar N.V. Br. J. Pharmacol. 136 (2002) 9